STEMPLER ENTERPRISES, INC. – Trademark Portfolio
Entity Type: 03
STEMPLER ENTERPRISES, INC. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 27 (Floor Coverings) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include IPRIN, MEDIQUE, MEDIPROXEN, MEDI-PHENYL, and MEDI FIRST PLUS. The owner is based in WILMINGTON, DE.
300 DELAWARE AVENUE
WILMINGTON, DE 19801
Showing of trademarks Trademarks
Trademark Classifications
STEMPLER ENTERPRISES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Carpets, rugs, mats and matting, linoleum and other materials for covering floors
Frequently Asked Questions
How many trademarks does STEMPLER ENTERPRISES, INC. have?
STEMPLER ENTERPRISES, INC. has 19 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned, 13 cancelled.
What trademark classes does STEMPLER ENTERPRISES, INC. file in?
STEMPLER ENTERPRISES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 27 (Floor Coverings). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are STEMPLER ENTERPRISES, INC.'s most well-known trademarks?
STEMPLER ENTERPRISES, INC.'s registered trademark portfolio includes well-known marks such as IPRIN, MEDIQUE, MEDIPROXEN, MEDI-PHENYL, and MEDI FIRST PLUS. These are among 5 currently registered trademarks in the portfolio.
What is STEMPLER ENTERPRISES, INC.'s trademark registration success rate?
STEMPLER ENTERPRISES, INC. has a 26% trademark registration rate, with 5 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.